SOLIGENIX, INC. — Earnings Release 2009

Mar 31, 2009

8-K 1 dor8kfinancial2008.htm DOR 8K ON FINANCIAL RESULTS 2008 dor8kfinancial2008.htm Licensed to: dk842 Document Created using EDGARizer 4.0.7.0 Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): March 31, 2009

Commission File No. 000-16929

DOR BIOPHARMA, INC.

(Exact name of small business issuer as specified in its charter)

DELAWARE	41-1505029
(State
or other jurisdiction of incorporation or organization)	(I.R.S.
Employer Identification Number)
29
Emmons Drive, Suite
C-10 Princeton,
NJ	08540
(Address
of principal executive offices)	(Zip
Code)
(609)
538-8200
(Issuer’s
telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. Results of Operations and Financial Condition.

On March 31, 2009, DOR BioPharma, Inc. issued a press release announcing its results of operations for the fiscal year ended December 31, 2008. A copy of the press release is attached as Exhibit 99.1 to this report. This information is not deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into any Securities Act registration statements.

Item 9.01. Financial Statements and Exhibits.

(c) Exhibits.

Exhibit No. Title

99.1 Press release issued by DOR BioPharma, Inc. on March 31, 2009.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DOR BIOPHARMA, INC.

| March
31, 2009 |
| --- |
| Christopher
J. Schaber, Ph.D. |
| President
and Chief Executive Officer |
| (Principal
Executive Officer) |

EXHIBIT INDEX

Exhibit No. Description

99.1 Press release issued by DOR BioPharma, Inc. on March 31, 2009.